3/ Spring Obesity Summit 2019

Most Important Messages from Obesity Conference 2019

Message one

In 2015 I attended a Columbia University preparation course for the ABOM boards.  He taught the same thing back then and I based my personal diet on it as well as the basis of my book,
The Chronic Disease of Obesity, published Feb. 2018
I developed the Sponge Syndrome theory in 2011 after hearing from Rudy Leibel at my first OMA meeting in Orlando.


Message Two
Case Studies with diet medications

Dr. Aronne presented several case studies using multiple diet medications

Message Three
Dr. Harold Bays said this was tremendous news:

1. Jardiance decreases heart disease link

My experience with GLT drug Invokana link

Conclusions of trial

"SGLT2 inhibition may emerge as an effective and safe adjunctive therapy for HF that promotes 

1-hemodynamic stability and

2- helps correct volume overload,

3- while avoiding the risks of volume depletion,

4-independent of effects on hyperglycemia.

 Nevertheless, the mechanisms responsible for the acute cardioprotective effects of SGLT2 inhibition, such as sodium and water homeostasis and plasma volume regulation, must be examined in diverse populations, including in patients with and without T2D, and in those with HFpEF and HFrEF.

 Furthermore, the therapeutic landscape will continue to evolve with the use of new agents that impact circulating volume, such endothelin-1A receptor antagonists (sodium retention) and angiotensin receptor-neprilysin inhibitors (natriuresis). The diabetes research community will also need to focus on understanding how these various agents interact in combination, both in terms of blood pressure, albuminuria, and cardiorenal benefits, and around the potential for adverse effects.109

In light of 

1-EMPA-REG OUTCOME, the 

2-CANVAS (with Invokana) Program, and

 studies with 

3-GLP-1RA agents,

 the management of patients with T2D and existing CVD is evolving.

 Because clinicians now have access to effective therapies to prevent cardiorenal events, future trials need to consider whether the demonstration of noninferiority is sufficient, or whether superiority should be targeted, especially for HF events.

 In addition, although existing trial evidence has demonstrated unexpectedly robust protection in patients with existing complications, it remains to be determined whether these agents will be similarly effective as primary prevention strategies."